Company Performance Metrics
Immunovadis discovers and develops monoclonal antibody therapies targeting HLA-G in the context of oncology. The company focuses on HLA-G molecules, which function as shields that protect cancer cells from immune recognition and destruction. Its research program is built on scientific work identifying HLA-G as a key immune escape mechanism in
tumors. Immunovadis designs functional monoclonal antibodies intended to bind and remove this HLA-G shield from malignant cells. By disrupting this barrier, its therapeutic candidates aim to enable the patient’s immune system to recognize and attack cancer cells. The organization operates as a biotechnology and biopharmaceutical developer with a pipeline centered on HLA-G–directed oncology therapeutics. Its activities span experimental research, antibody engineering, and preclinical and clinical development of targeted cancer therapies.
